Ayushman Bharat Digital Mission crosses 90 crore ABHA accounts milestone

IMT News Desk
IMT News Desk
· 2 min read
ABDM crosses 90 crore ABHA health accounts, marking a major milestone in India’s digital health push & expanding access to unified, patient‑centric care

The Ayushman Bharat Digital Mission (ABDM) has crossed the landmark milestone of 90 crore Ayushman Bharat Health Accounts (ABHAs) across the country, marking a major step in India’s push towards a connected and citizen‑centric digital health ecosystem. Implemented by the National Health Authority (NHA) under the Ministry of Health and Family Welfare, ABDM enables citizens to create a unique 14‑digit ABHA that serves as their digital health identity, allowing them to securely link, access and share their health records with consent.

According to official data, the pace of ABHA creation has accelerated consistently since the launch of ABDM, with cumulative accounts rising from 14.7 crore in 2021 to 30.4 crore in 2022, 50.6 crore in 2023, 72.2 crore in 2024, then 84.5 crore in 2025, and surpassing 90 crore in 2026. Uttar Pradesh leads the country with over 15.3 crore ABHA accounts, followed by Rajasthan and Maharashtra with about 7.1 crore each, Bihar with 6.3 crore, and West Bengal with 5.9 crore.

The government highlighted that women account for nearly half of all ABHA holders, with females constituting around 49.75% of the total accounts created so far, reflecting efforts to ensure inclusive participation in the digital health ecosystem. Officials said the growing footprint of ABHA across states and Union Territories demonstrates increasing adoption of ABDM by citizens, healthcare providers and ecosystem partners ranging from hospitals and clinics to digital health platforms.

Dr Sunil Kumar Barnwal, CEO of the National Health Authority, said the creation of over 90 crore ABHAs underscores the collective commitment of citizens, states, UTs and partners to transforming healthcare delivery through digital tools. He noted that as ABDM adoption deepens, ABHA‑linked health records will help ensure continuity of care, reduce reliance on paper‑based records and support more seamless, transparent and patient‑centric services across public and private facilities.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk